Acadia Pharmaceuticals Inc. (ACAD)
Nasdaq · Common stock · Pharmaceutical Preparations
As of Oct 21, 4:00 PM ET15 min delayedAbout 15 minutes behind the market. Every member plan is real time.
Follow ACAD in real time
Real-time quotes, Pro Charting, the scanner and the alert feed on ACAD and every other US listing.
Start 5 days freeTry Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
ACAD at a glance
Key statistics
$3.52B
Market capitalization
- Previous close
- $20.44
- Open
- $20.44
- Day range
- $20.10 – $20.57
- Volume
- 1.41M
- Average volume (30 sessions)
- 2.16M
- Shares outstanding
- 172.31M
- Price / earnings
- 9.3
- Earnings per share
- $2.21
- Price / book
- 2.7
- Price / sales
- 3.1
- Beta (1 year, vs SPY)
- 0.71
Where the price sits in its year
52-week range
14% of the range
- Below the 52-week high
- -34.8%
- Above the 52-week low
- +9.8%
Completed sessions through Oct 21, 2026
Technical snapshot
Below its 50-day and 200-day averages
- 20-day average
- $19.95+1.2%
- 50-day average
- $25.00-19.2%
- 200-day average
- $23.91-15.6%
Between the conventional 30 and 70 bands.
+4.9%
1 week
-23.6%
1 month
-18.7%
3 months
-24.4%
Year to date
-3.6%
1 year
Price change over each window, from completed sessions. Past performance does not indicate future results.
Every plan: MACD, ATR, the 20- and 50-day ranges, five-year and all-history extremes and the full indicator set, live on Pro Charting.The member platform, in real time
What members do with ACAD
ACAD on Pro Charting
Every intraday interval in real time, the drawing kit and the full set of technical studies on ACAD.
See the plans →
Every planScreen names like ACAD
The real-time scanner: price, volume, technical, fundamental and chart-pattern filters across the whole US market.
See the plans →
Analysis Tools OnlySet a price line on ACAD
Put ACAD on your watchlist, draw the levels you care about, and My Dashboard tracks where it trades against them.
See the plans →
Stock Alerts + ToolsOpen alerts on ACAD
See whether there is an open premium alert on ACAD, with its entry, stop and exit, each one reviewed by an analyst before it is sent.
See the plans →
From the public news wire
ACAD headlines
- ACADIA Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (25 Ratings)
Benzinga · Apr 30, 2024
- Cracking The Code: Understanding Analyst Reviews For ACADIA Pharmaceuticals
Benzinga · Apr 10, 2024
- Expert Ratings For ACADIA Pharmaceuticals
Benzinga · Mar 25, 2024
- ACADIA Pharmaceuticals, Ocular Therapeutix, Asana And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Benzinga · Mar 12, 2024
- Acadia Pharma’s stock falls 15% after failed drug trial
MarketWatch · Mar 11, 2024
- Beyond The Numbers: 13 Analysts Discuss ACADIA Pharmaceuticals Stock
Benzinga · Feb 28, 2024
- Analyst Scoreboard: 12 Ratings For ACADIA Pharmaceuticals
Benzinga · Jan 24, 2024
SEC Form 4, most recent first
Insider filings
Schneyer Mark C.
−5.8K
EVP, CHIEF FINANCIAL OFFICER · Open-market sale
$169.64K · Aug 5, 2026
Schneyer Mark C.
−5.0K
EVP, CHIEF FINANCIAL OFFICER · Open-market sale
$145.00K · Aug 6, 2026
Schneyer Mark C.
+14.3K
EVP, CHIEF FINANCIAL OFFICER · Option exercise
$254.97K · Aug 6, 2026
Schneyer Mark C.
+5.8K
EVP, CHIEF FINANCIAL OFFICER · Option exercise
$104.35K · Aug 5, 2026
Schneyer Mark C.
−14.3K
EVP, CHIEF FINANCIAL OFFICER · Option exercise
· Aug 6, 2026
Schneyer Mark C.
−5.8K
EVP, CHIEF FINANCIAL OFFICER · Option exercise
· Aug 5, 2026
Schneyer Mark C.
−9.3K
EVP, CHIEF FINANCIAL OFFICER · Open-market sale
$272.60K · Aug 6, 2026
Thompson Elizabeth H.Z.
+32.3K
EVP, Head of Research & Dev · Option exercise
· Jul 29, 2026
About Acadia Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise into making a difference for underserved neurological and rare disease communities around the world. It has two franchises in neurological and rare diseases. Its neurological disease franchise is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. FDA for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.
- Exchange
- Nasdaq
- Security
- Common stock
- Industry
- Pharmaceutical Preparations
- Headquarters
- San Diego, CA
- Employees
- 798
- Listed since
- May 27, 2004
- Website
- acadia.com
Pick the desk that fits how you trade
Analysis Tools Only for the real-time scanner, Pro Charting and the research desk. Stock Alerts + Tools for the human-reviewed alert feed. Premium Membership for both, at one price.
Try Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
Other plans from $39 a month. Pay by card, Apple Pay, Google Pay, Link, Cash App Pay or Amazon Pay through Stripe.